Publications
- Summary of recommendations 2013 "Diagnosis and treatment of systemic AL amyloidosis"2013 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma2013 | First Faculty of Medicine
- Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma2013 | First Faculty of Medicine
- Continuous lenalidomide treatment for newly diagnosed multiple myeloma2012 | First Faculty of Medicine
- Treatment of multiple myeloma with lenalidomide in 20122012 | First Faculty of Medicine
- Lenalidomide in the first and additional lines of therapy for multiple myeloma2012 | First Faculty of Medicine
- Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma2011 | First Faculty of Medicine
- An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation2011 | First Faculty of Medicine
- Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma2010 | First Faculty of Medicine
- Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy2010 | First Faculty of Medicine
Loading network view...